Clinical trials: Follicular Lymphoma
All Malignancies, Advanced Malignancies
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
The participants of this study will have advanced malignancies (also known as advanced cancer). The main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the tazemtostat (the study drug) when…
- Conditions
- All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor
- Trial name
- NCT04537715
- Testing
- Tazemetostat, Itraconazole, Rifampin
- Where
- 10 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Epizyme, Inc.
Non-Hodgkin's Lymphoma
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's…
- Trial name
- NCT00057447
- Testing
- Interferon Gamma-1b, Rituximab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- InterMune
Lymphoma, Follicular
Autologous Vaccine for Follicular Lymphoma
This phase I study will evaluate the safety and tolerability of an autologous idiotype vaccine manufactured by magnICON technology for patients with relapsed follicular lymphoma who are in complete or partial remission following…
- Trial name
- NCT01022255
- Testing
- Autologous FL vaccine
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Icon Genetics GmbH
Nasolabial Fold
Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® L in Correcting Moderate or Severe Nasolabial Folds
The utilization of minimally invasive techniques has brought about a transformative shift in the approach to face rejuvenation, potentially representing one of the most notable advancements in facial plastic surgery in recent…
- Trial name
- NCT06828224
- Testing
- KOS® L
- Where
- Romania
- Volunteers
- 34 people
- Sponsor
- Quantum Beauty Kozmetik
Marginal Zone Lymphoma, Follicular Lymphoma
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)
- Trial name
- NCT04849351
- Testing
- HMPL-689
- Where
- 58 sites in China
- Volunteers
- 178 people
- Sponsor
- Hutchison Medipharma Limited
Lymphoma
Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)
The purpose of this study is to evaluate the safety, tolerability, and efficacy of vorinostat (MK-0683) in participants with relapsed and/or refractory follicular lymphoma.
- Trial name
- NCT00875056
- Testing
- Vorinostat
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
CLL/SLL, NHL
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
- Conditions
- CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT05665062
- Testing
- SYNCAR-001, STK-009, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Synthekine
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Moderate and Severe Plaque Psoriasis
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
This study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease…
- Trial name
- NCT00885196
- Testing
- AEB071
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 336 people
- Sponsor
- Novartis Pharmaceuticals
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Product: PSB202 is a novel biological entity consisting of two engineered monoclonal antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized anti-CD37 IgG1 (PSB107), that target B-cells.
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma
- Trial name
- NCT05003141
- Testing
- PSB202
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 110 people
- Sponsor
- Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Lymphoma, Follicular
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.
- Trial name
- PREMIER (NCT00308087)
- Testing
- Sargramostim (Leukine), Rituximab
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- Genzyme, a Sanofi Company
Renal Insufficiency
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
Multi-center, open-label, single-dose study to assess the PK of a single oral dose of 3 mg CC-122 in subjects with mild, moderate, and severe renal impairment as compared to sex, age (± 15 years), and weight (± 20%) matched…
- Trial name
- NCT03097016
- Testing
- CC-122
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Celgene
Follicular Lymphoma, Marginal Zone Lymphoma
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
The goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
- Trial name
- ZUMA-5 (NCT03105336)
- Testing
- Axicabtagene ciloleucel, Cyclophosphamide, Fludarabine
- Where
- 19 sites in United States, France
- Volunteers
- 159 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.
- Trial name
- NCT02384954
- Testing
- Rituximab, N-803
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Altor BioScience
Follicular Lymphoma, Diffuse Large B Cell Lymphoma
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy…
- Conditions
- Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05255354
- Testing
- ClonoSEQ
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Adaptive Biotechnologies
Follicular Lymphoma, B-cell Lymphoma
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with Follicular Lymphoma (FL).
- Conditions
- Follicular Lymphoma, B-cell Lymphoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT01980654
- Testing
- Ibrutinib, rituximab
- Where
- 12 sites in United States
- Volunteers
- 80 people
- Sponsor
- Pharmacyclics LLC.
Lymphoma, Follicular
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients
To investigate the efficacy in two dose regimens of ofatumumab in combination with CHOP (cyclophosphamide,doxorubicin, vincristine,prednisolone) in previously untreated patients with Follicular Lymphoma (FL)
- Trial name
- MUNIN (NCT00494780)
- Testing
- Ofatumumab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Lymphoma, Non-Hodgkin
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
This research study will test OT-82, which is an investigational ("research" or "experimental" ) drug. The study has two stages (Stage 1 and Stage 2).
- Conditions
- Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell
- Trial name
- NCT03921879
- Testing
- OT-82 Dose Escalation, OT-82 Dose Expansion
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Oncotartis, Inc.
Non-Hodgkin Lymphoma, T-Cell Lymphoma
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
The SCORE-NHL study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with aggressive Stage I to IV non-Hodgkin Lymphoma (NHL).
- Conditions
- Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
- Trial name
- SCORE-NHL (NCT07750886)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Natera, Inc.